12:00 AM
 | 
Aug 21, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pafase: Began Phase III testing

Icos Corp. (ICOS), Bothell, Wash.
Product: Pafase
Business: Autoimmune/Inflammation
Therapeutic category: Immune modulation
Target:

Read the full 57 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >